Skip to content

Depression research published in 2018

Page 7 of 10: studies 121 to 140 of 186, newest first. Back to the depression overview

Studies

Amigas Latinas Motivando el Alma (ALMA): an Evaluation of a Mindfulness Intervention to Promote Mental Health among Latina Immigrant Mothers.

The journal of behavioral health services & research April 1, 2018 Daron Ryan, Serena Maurer, Liliana J. Lengua et al.

Latina immigrants are at increased risk for poor mental health. Amigas Latinas Motivando el Alma (ALMA) is a group-based intervention to reduce symptoms of depression, anxiety, and stress among Latina immigrants. Based on participants' feedback and growing evidence supporting mindfulness as a way to reduce stress and improve mental health, additional sessions of the ALMA intervention were...

Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.

Journal of Psychopharmacology April 2018 Verònica Gálvez, Adrienne Li, Christina Huggins et al.

Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. This randomised, double-blind, placebo-controlled pilot study compared a 4-week course...

Compassion-Based Meditation in African Americans: Self-Criticism Mediates Changes in Depression.

Suicide and Life-Threatening Behavior April 1, 2018 Suzanne B Johnson, Bradley L Goodnight, Huaiyu Zhang et al.

This study examines self-criticism as a mechanism through which compassion meditation reduces depressive symptoms in low-income African American men and women (N = 59) who had recently attempted suicide. After completing several measures, including the Levels of Self-Criticism Scale and Beck Depression Inventory-II, participants were randomly assigned to receive either a six-session compassion...

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.

Journal of Affective Disorders April 1, 2018 Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak et al. 57 citations

Background: Natural speech analytics has seen some improvements over recent years, and this has opened a window for objective and quantitative diagnosis in psychiatry. Here, we used a machine learning algorithm applied to natural speech to ask whether language properties measured before psilocybin for treatment-resistant can predict for which patients it will be effective and for which it will...

DOI: 10.1016/j.jad.2018.01.006 (opens in new tab) Psychedelic therapy Psilocybin therapy Psilocybin treatment Depression treatment +17

Effect of Seminar on Compassion on student self-compassion, mindfulness and well-being: A randomized controlled trial.

Journal of American College Health March 22, 2018 Celine M Ko, Fran Grace, Gilbert N Chavez et al.

Objective: Mindfulness-based interventions have been shown to have psychological benefits in college students. We explored the effects of an academic Seminar on Compassion on student psychological health. Participants: Forty-one participants (14 male, 27 female, mean age 19.8 ± 1.4 years) were assessed pre- and post- spring semesters 2013 and 2014. Methods: Students were randomized to the...

Effects of Mindfulness-Based Art Therapy on Psychological Symptoms in Patients with Coronary Artery Disease.

Journal of Korean medical science March 19, 2018 Seung‐ho Jang, Jae Hee Lee, Hye-Jin Lee et al.

Background: Mindfulness-based art therapy (MBAT) induces emotional relaxation in coronary artery disease (CAD) patients, and is a treatment known to improve psychological stability. The objective of this study was to evaluate the treatment effects of MBAT for CAD patients. Methods: A total of 44 CAD patients were selected as participants, 21 patients belonged to a MBAT group, and 23 patients...

Relationship of Mindfulness to Distress and Cortisol Response in Adolescent Girls At-Risk for Type 2 Diabetes.

Journal of Child and Family Studies March 19, 2018 Amanda Skoranski, Nichole R Kelly, Rachel M Radin et al.

Altered stress response theoretically contributes to the etiology of cardiometabolic disease. Mindfulness may be a protective buffer against the effects of stress on health outcomes by altering how individuals evaluate and respond to stress. We engaged adolescent girls at risk for developing Type 2 diabetes in a cold-pressor test in order to determine the relationship of dispositional...

Interactive effects of ghrelin and ketamine on forced swim performance: Implications for novel antidepressant strategies.

Neuroscience Letters March 16, 2018 Jeffrey Landrigan, Farah Shawaf, Zach Dwyer et al.

The efficacy of ketamine to alleviate depressive symptoms has promoted a wealth of research exploring alternate therapeutic targets for depression. Given the caveats of ketamine treatment taken together with the increasingly greater emphasis on combinatorial therapeutic approaches to depression, we sought to asses whether the hypothalamic "hunger hormone", ghrelin, would augment the effects of...

Nightmares in United States Military Personnel With Sleep Disturbances.

Journal of Clinical Sleep Medicine March 15, 2018 Jennifer L Creamer, Matthew S. Brock, Panagiotis Matsangas et al.

Study objectives: Sleep disturbances are common in United States military personnel. Despite their exposure to combat and trauma, little is known about nightmares in this population. The purpose of this study was to describe the prevalence and associated clinical and polysomnographic characteristics of nightmares in United States military personnel with sleep disturbances. Methods:...

Phase 2 study finds intranasal esketamine effective in treatment‐resistant depression

The Brown University Psychopharmacology Update March 9, 2018

Patients with treatment‐resistant depression who received intranasal esketamine as adjunctive therapy with an antidepressant experienced greater symptom improvement than patients receiving adjunctive placebo, a multiphase study with 67 participants has found. The antidepressant effect seen in the study was dose‐related, and adverse events led to study discontinuation in only a small number of...

Treating Subthreshold Depression in Primary Care: A Randomized Controlled Trial of Behavioral Activation With Mindfulness.

Annals of family medicine March 1, 2018 Samuel Y S Wong, Yu Ying Sun, Aaroy T Y Chan et al.

Purpose: We undertook a randomized controlled trial to assess the efficacy of group-based behavioral activation with mindfulness (BAM) for treating subthreshold depression in primary care in Hong Kong. Methods: We recruited adult patients aged 18 years or older with subthreshold depression from public primary care clinics and randomly assigned them to a BAM intervention group or a usual care...

Cognitive reactivity as outcome and working mechanism of mindfulness-based cognitive therapy for recurrently depressed patients in remission.

Cognition & Emotion March 2018 Mira B. Cladder-Micus, Joël R Van Aalderen, A R T Donders et al.

Major depressive disorder is a prevalent condition with high relapse rates. There is evidence that cognitive reactivity is an important vulnerability factor for the recurrence of depression. Mindfulness-based interventions are designed to reduce relapse rates, with cognitive reactivity as one of the proposed working mechanisms. In a randomised controlled trial we compared the effect of...

Effectiveness of group cognitive behavioral therapy with mindfulness in end-stage renal disease hemodialysis patients.

Kidney research and clinical practice March 2018 Bo Kyung Sohn, Yun Kyu Oh, Jung-Seok Choi et al.

Many patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) experience depression. Depression influences patient quality of life (QOL), dialysis compliance, and medical comorbidity. We developed and applied a group cognitive behavioral therapy (CBT) program including mindfulness meditation for ESRD patients undergoing HD, and measured changes in QOL, mood, anxiety, perceived...

Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.

Frontiers in Pharmacology March 1, 2018 Emmanuelle A. D. Schindler, Ryan M Wallace, Jordan Sloshower et al.

Recent reports on the effects of psychedelic-assisted therapies for mood disorders and addiction, as well as the effects of psychedelics in the treatment of cluster headache, have demonstrated promising therapeutic results. In addition, the beneficial effects appear to persist well after limited exposure to the drugs, making them particularly appealing as treatments for chronic neuropsychiatric...

Novel treatment options in depression and psychosis

Neuropsychiatric Disease and Treatment March 1, 2018 Eva Češková, Petr Šilhán

Eva Ceskova, Petr Silhan Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech Republic Abstract: In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing)...

DOI: 10.2147/ndt.s157475 (opens in new tab) Aripiprazole Lurasidone Schizophrenia object-oriented programming Intensive care medicine +1

Glutamatergic Modulators in Depression

Harvard Review of Psychiatry February 21, 2018 Ioline D. Henter, Rafael Teixeira de Sousa, Carlos A. Zarate 94 citations

LEARNING OBJECTIVE: After participating in this activity, learners should be better able to evaluate the evidence supporting the antidepressant effects of glutamatergic modulators.Both preclinical and clinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders such as bipolar depression and major depressive disorder. In particular, rapid reductions...

DOI: 10.1097/hrp.0000000000000183 (opens in new tab) Glutamatergic Dextromethorphan Pharmacology Nmda receptor +5

Sleep disorder prevalence in at-risk adolescents and potential effects of nightmare triad syndrome.

International journal of adolescent medicine and health February 17, 2018 Natalia D McIver, Barry Krakow, Jessica Krakow et al.

Objective At-risk high school students, those considered to have a higher probability for academic failure or dropping out, were assessed for various sleep disorders. Effects were compared between students with and without the nightmare triad syndrome (NTS+), the sleep disorders' cluster of frequent nightmares, insomnia disorder and suspected sleep-disordered breathing (SDB). Methods Data were...

Features of Dissociation Differentially Predict Antidepressant Response to Ketamine in Treatment-Resistant Depression

Journal of Affective Disorders February 17, 2018 Mark J. Niciu, Bridget J. Shovestul, Brittany A. Jaso et al. 134 citations

Background Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response. This follow-up study investigated whether antidepressant efficacy is uniquely related to dissociative symptom clusters. Methods Treatment-resistant patients with major depressive disorder (MDD) or bipolar disorder (BD) (n=126) drawn...

Mindfulness self-help interventions for symptoms of depression, anxiety and stress: Review and meta-analysis

February 12, 2018 Kristy Martin, Nima Golijani-Moghaddam, R. Das Nair

Background: Mindfulness-based therapy has been found to be an efficacious treatment for a range of mental and physical health conditions. There are increasing efforts to deliver benefits of mindfulness through less intensive/more accessible modalities but whether this efficacy holds in lower-intensity forms is unknown. This paper reviews the effectiveness of mindfulness delivered in a self-help...

Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy.

Journal of Psychiatric Research February 10, 2018 Andrew P. Allen, Maura Naughton, J. Dowling et al. 53 citations

Current first-line antidepressants can take weeks or months to decrease depressive symptoms. Low dose ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows potential for a more rapid antidepressant effect, with efficacy also evident in previously treatment-resistant populations. However, a greater understanding of the physiological mechanisms underlying such effects is required....